FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer

April 12, 2019 -- The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news